Media coverage about Biostar Pharmaceuticals (NASDAQ:BSPM) has been trending somewhat positive on Thursday, Accern reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biostar Pharmaceuticals earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.4875280582287 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Biostar Pharmaceuticals traded down $0.03, reaching $2.18, during trading hours on Thursday, Marketbeat.com reports. 17,432 shares of the company were exchanged, compared to its average volume of 609,665. The stock has a market capitalization of $5.91 million, a P/E ratio of 3.20 and a beta of 2.41. Biostar Pharmaceuticals has a 12 month low of $1.18 and a 12 month high of $5.97.
About Biostar Pharmaceuticals
Biostar Pharmaceuticals, Inc develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B.
Receive News & Ratings for Biostar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.